New Cardiovascular Research Study Findings Have Been Reported by Investigators at Yale University School of Medicine (Cardiovascular Morbidity and Mortality In Lean Vs. Non-lean Masld: a Comprehensive Meta-analysis).

A new research study conducted by investigators at Yale University School of Medicine examines cardiovascular outcomes in lean and non-lean individuals with metabolic dysfunction-associated steatotic liver disease (MASLD). The study found that lean MASLD patients have a 50% higher risk of cardiovascular mortality compared to non-lean MASLD patients. However, lean MASLD patients had lower odds of major adverse cardiovascular events, cardiovascular disease, hypertension, and dyslipidemia compared to non-lean MASLD patients. The research concludes that despite a favorable cardiometabolic profile, lean individuals with MASLD face an elevated risk of cardiovascular mortality. [Extracted from the article]

Copyright of Cardiovascular Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)